SCHEMBL186917

SCHEMBL186917

COC(=O)c1ccc(OC)c2nc(C)nn12

nearest known ligand 0.58

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 11/20 0.58
PDE4D Q08499 3/20 0.44
ALDH1A1 P00352 4/20 0.43
HPGD P15428 2/20 0.43
PDE4B Q07343 1/20 0.40
PDE4C Q08493 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
POLB P06746 1/20 0.38
MAPT P10636 1/20 0.38
HTT P42858 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
LMNA P02545 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL187938 0.80 PDE4D (0.68) PDE4APDE4DPDE4BPDE4C
SCHEMBL187715 0.76 PDE4A (0.64) PDE4AALDH1A1HPGDPOLBMAPT
SCHEMBL187799 0.75 PDE4A (0.66) PDE4APDE4D
SCHEMBL187259 0.75 PDE4D (0.57) PDE4APDE4DHPGDPDE4BPDE4C
SCHEMBL187703 0.74 PDE4A (1.00) PDE4APDE4DPDE4BPDE4C
SCHEMBL544040 0.73 EGLN2 (0.43) PDE4AALDH1A1HPGDL3MBTL1MAPT
SCHEMBL14918993 0.69 KDM4E (0.71) ALDH1A1HPGDL3MBTL1MAPTLMNA
SCHEMBL31056002 0.69 PTK2 (0.40) PDE4APDE4DPDE4BPDE4CL3MBTL1
SCHEMBL18952870 0.68 CYP1A2 (0.40) PDE4AALDH1A1HPGDMAPTSMN1; SMN2
SCHEMBL18952854 0.68 CYP1A2 (0.38) PDE4AALDH1A1HPGDL3MBTL1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8829190-B2 Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases LEO PHARMA A/S (DK) 2014-09-09 US disclosed
US-8829190-B2 Triazolopyridines as phosphodiesterase inhibitors for treatment of dermal diseases LEO PHARMA A/S (DK) 2014-09-09 US disclosed
EP-2146989-B1 TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES LEO PHARMA AS (DK) 2012-01-04 EP disclosed
EP-2146989-B1 TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES LEO PHARMA AS (DK) 2012-01-04 EP disclosed
US-20100113442-A1 TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES FELDING JAKOB 2010-05-06 US disclosed
US-20100113442-A1 TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES FELDING JAKOB 2010-05-06 US disclosed
EP-2146989-A1 TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES Leo Pharma A/S (DK) 2010-01-27 EP disclosed
WO-2008125111-A1 TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES LEO PHARMA A/S (DK) 2008-10-23 WO disclosed
WO-2008125111-A1 TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES LEO PHARMA A/S (DK) 2008-10-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100113442-A1 TRIAZOLOPYRIDINES AS PHOSPHODIESTERASE INHIBITORS FOR TREATMENT OF DERMAL DISEASES PDE5A, PDE3A, PDE3B PDE4A 6/4885PDE4D 9/4885ALDH1A1 760/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.